AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
BioGen's Loss of Money
When you took over at BioGen in 2010, the company was losing money and not making as much as it should have. You felt like they were doing too many things: multiple sclerosis, oncology, neurodegeneration. "BioGen isn't nearly big enough to do all those different things with excellence," he says. 'We got the company shaped up'